Discontinued — last reported Q3 '23
Kimberly-Clark Equity Method Investments increased by 16.1% to $383.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 8.2%, from $354.00M to $383.00M. Over 5 years (FY 2020 to FY 2025), Equity Method Investments shows relatively stable performance with a 1.9% CAGR.
An increase indicates strategic expansion through partnerships or joint ventures, while a decrease may signal divestments or impairment.
These are investments in entities where the company exercises significant influence but does not have full control. The...
Varies significantly based on corporate strategy; common in healthcare companies that partner with biotech startups or specialized diagnostic firms.
equity_method_investments| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $350.00M | $340.00M | $290.00M | $266.00M | $270.00M | $266.00M | $238.00M | $281.00M | $299.00M | $320.00M | $306.00M | $364.00M | $381.00M | $362.00M | $314.00M | $354.00M | $359.00M | $355.00M | $330.00M | $383.00M |
| QoQ Change | — | -2.9% | -14.7% | -8.3% | +1.5% | -1.5% | -10.5% | +18.1% | +6.4% | +7.0% | -4.4% | +19.0% | +4.7% | -5.0% | -13.3% | +12.7% | +1.4% | -1.1% | -7.0% | +16.1% |
| YoY Change | — | — | — | — | -22.9% | -21.8% | -17.9% | +5.6% | +10.7% | +20.3% | +28.6% | +29.5% | +27.4% | +13.1% | +2.6% | -2.7% | -5.8% | -1.9% | +5.1% | +8.2% |